Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone in Alzheimer's Disease Psychosis
NCT00287742Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2002
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Risperidone with Placebo (2 arms). Primary endpoint: Change in Behavioral Pathology in Alzheimer's Disease (BEHAVE-AD) psychotic symptom cluster score at Week 9. Started Mar 2002; status: terminated.
02
Drugs
risperidone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00287742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00287742.